The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of enriched specific subset of immune cells nearby tumor associated macrophage (TAM) with pathologic complete response (pCR) of concurrent chemoradiotherapy followed by nivolumab in locally advanced rectal cancer (LARC).
 
Mitsuho Imai
Patents, Royalties, Other Intellectual Property - 1. ?NCC's Reference: #2023-03 Filing number (Filing date): US 63/468,666 (2023.05.24) Title: METHOD OF USING AN ARTIFICIAL INTELLIGENCE-POWERED WHOLE SLIDE IMAGE (WSI) ANALYSIS TO PREDICT TUMOR RESPONSE TO SUBSEQUENT IMMUNE CHECKPOINT INHIBITOR TREATMEN
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuichiro Tsukada
No Relationships to Disclose
 
Koji Inamori
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Mamoru Uemura
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Akinobu Taketomi
No Relationships to Disclose
 
Takao Fujisawa
Honoraria - Amelief; Merck Serono
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Motohiro Kojima
No Relationships to Disclose
 
Shohei Koyama
Consulting or Advisory Role - Kaken Pharmaceutical
Research Funding - Otsuka
 
Sanghoon Song
Employment - Lunit
Stock and Other Ownership Interests - Lunit
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Y-Biologics
Consulting or Advisory Role - Genome & Company; Idience; Medpacto; PIN therapeutics; Selecxine; Y-Biologics
 
Hiroyoshi Nishikawa
Stock and Other Ownership Interests - Cellian-Biclo; Sustainable Cell Therapeutics
Honoraria - Amgen; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; MSD K.K; Ono Pharmaceutical
Research Funding - Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Debiopharm Group; Fujifilm; Hitachi; MiraBiologics Inc.; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; Taiho Pharmaceutical
 
Masaaki Ito
Employment - ASAHI INTECC
Leadership - Jmees Inc.
Stock and Other Ownership Interests - Jmees Inc.
Honoraria - Applied Medical Japan; Bayer Yakuhin; Covidien; Fujifilm; Johnson & Johnson K.K. Medical Company; Kaken Pharmaceutical; MC Medical, Inc.; Nippon Covidien Ltd.; Olympus; Olympus; Taiho Pharmaceutical
Consulting or Advisory Role - ASAHI INTECC
Research Funding - Astellas Pharma; Fujifilm; Fujita Medical Instruments Co., Ltd.; Indivumed; Intelligent Surfaces, Inc.; Kawasumi Laboratories, Incorporated; Muranaka Medical Instruments Co., Ltd.; Nippon Covidien Ltd.; Olympus; Sumitomo Chemical; Sumitomo Chemical Co., Ltd.; Surg storage CO., Ltd.
Patents, Royalties, Other Intellectual Property - BMG Inc.; EBM Co.; Fujita Medical Instruments CO., Ltd.; Muranaka Medical Instruments Co.; Olympus; Sumitomo Chemical; Takano Company Limited
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)